Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study and up to  months after the last dose of atezolizumab \r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within  weeks prior to cycle , day  or at any time during the study
Administration of a live, attenuated vaccine within  weeks before randomization or anticipation that such a live, attenuated vaccine will be required during the study and up to  months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within  weeks prior to cycle , day  or at any time during the study
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study and up to  months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within  weeks prior to cycle , day  or at any time during the study
Administration of a live, attenuated vaccine within  days prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study and up to  months after the last dose of atezolizumab; Note: influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within  days prior to randomization or at any time during the study
Patients must not have received of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study and up to  months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within  weeks prior to cycle , day  or at any time during the study
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study and up to  months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within  weeks prior to cycle , day  or at any time during the study
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study and up to  months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within  weeks prior to cycle , day  or at any time during the study
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study and up to  months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within  weeks prior to cycle , day  or at any time during the study
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live attenuated vaccine will be required during the study; inactivated vaccines (such as hepatitis A or polio vaccines) are permitted during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must no receive live attenuated influenza vaccine (e.g., FluMist) within  weeks prior to cycle , day  and for at least  weeks after the last dose
Administration of a live, attenuated vaccine within  weeks before Cycle , Day  or anticipation that such a live attenuated vaccine will be required during the study. Influenza vaccination should be given during influenza season only. Participants must not receive live, attenuated influenza vaccine within  weeks prior to Cycle , Day , at any time during the study or  months after the last dose of atezolizumab
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study. Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within  weeks prior to cycle , day  or at any time during the study.
GENERAL: Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within  weeks prior to cycle , day  or at any time during the study.
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study and up to  months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only; patients must not receive live, attenuated influenza vaccine within  weeks prior to cycle , day  or at any time during the study
Administration of a live, attenuated vaccine within  weeks before start of study treatment or anticipation that such a live, attenuated vaccine will be required during the study.\r\n* Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within  weeks prior to start of study treatment or at any time during the study.
Administration of a live, attenuated vaccine within  weeks prior to initiation of study treatment with atezolizumab or anticipation that such a live, attenuated vaccine will be required during the study; influenza vaccination should be given during influenza season only (approximately October to May in the Northern Hemisphere); patients must agree not to receive live attenuated influenza vaccine (e.g., FluMist) within  days prior to study treatment, during treatment, or within  days following the last dose of atezolizumab
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study a) Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within  weeks prior to cycle , day  or at any time during the study
Patients who received a live, attenuated vaccine =<  days before study treatment or are anticipated to require such a live attenuated vaccine are not eligible\r\n* NOTE: Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) =<  days prior to study registration or at any time during the study
Administration of a live, attenuated vaccine within  weeks before cycle day  or anticipation that such a live attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); subjects must not receive live, attenuated influenza vaccine (e.g., FluMist) within  weeks prior to cycle  day  or at any time during the study
Administration of a live, attenuated vaccine =<  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) =<  weeks prior to cycle , day  or at any time during the study
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within  weeks prior to cycle , day  or at any time during the study
Administration of a live, attenuated vaccine within  weeks before enrollment or anticipation that such a live attenuated vaccine will be required during the study or for  months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March)\r\n* Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within  weeks prior to enrollment, at any time during the study, or for  months after the last dose of atezolizumab
Patients who received a live, attenuated vaccine =<  days before study registration or are anticipated to require such a live attenuated vaccine are not eligible; NOTE: Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) =<  days prior to study registration or at any time during the study
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study; influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within  weeks prior to cycle , day  or at any time during the study
Patients who have had a live, attenuated vaccine within  weeks before initiation of study treatment or anticipation that such a live, attenuated vaccine will be required during the study and up to  months after the last dose of atezolizumab.\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within  weeks before initiation of study treatment or at any time during the study
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study. (Influenza vaccination should be given during influenza season only [approximately October to March]. Patients must not receive live, attenuated influenza vaccine [e.g., FluMist] within  weeks prior to cycle , day  or at any time during the study.)
Administration of a live, attenuated vaccine within  days before week , day  or anticipation that such a live attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only; patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within  weeks prior to week , day  or at any time during the study
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within  weeks prior to cycle , day  or at any time during the study
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study and up to  months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within  weeks prior to cycle , day  or at any time during the study and until  months after the last dose of atezolizumab
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within  weeks prior to cycle , day  or at any time during the study
Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within  weeks prior to Cycle , Day  or at any time during the study.
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live attenuated vaccine will be required during the study;\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within  weeks prior to cycle , day  or at any time during the study
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study and up to  months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within  weeks prior to cycle , day  or at any time during the study
Administration of a live, attenuated vaccine within  weeks before treatment start or anticipation that such a live attenuated vaccine will be required during the study; influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within  weeks prior to treatment start or at any time during the study
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within  weeks prior to cycle , day  or at any time during the study
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study and up to  months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within  weeks prior to cycle , day  or at any time during the study
Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within  weeks prior to Cycle , Day  or at any time during the study.
Influenza vaccination with live attenuated vaccine in the  weeks prior to randomization
Subjects who have already received the seasonal influenza vaccine in the current influenza vaccination season
